PE20231169A1 - Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas - Google Patents

Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas

Info

Publication number
PE20231169A1
PE20231169A1 PE2023000716A PE2023000716A PE20231169A1 PE 20231169 A1 PE20231169 A1 PE 20231169A1 PE 2023000716 A PE2023000716 A PE 2023000716A PE 2023000716 A PE2023000716 A PE 2023000716A PE 20231169 A1 PE20231169 A1 PE 20231169A1
Authority
PE
Peru
Prior art keywords
administration
increase
human subject
compared
amount
Prior art date
Application number
PE2023000716A
Other languages
English (en)
Spanish (es)
Inventor
Diana Kerwin
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of PE20231169A1 publication Critical patent/PE20231169A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PE2023000716A 2020-08-27 2021-08-27 Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas PE20231169A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071257P 2020-08-27 2020-08-27
PCT/US2021/048084 WO2022047249A1 (en) 2020-08-27 2021-08-27 Methods for the treatment of cardiovascular disease with cyclodextrins

Publications (1)

Publication Number Publication Date
PE20231169A1 true PE20231169A1 (es) 2023-07-26

Family

ID=80353287

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023000716A PE20231169A1 (es) 2020-08-27 2021-08-27 Metodos para el tratamiento de enfermedades cardiovasculares con ciclodextrinas

Country Status (14)

Country Link
US (2) US20240000826A1 (cg-RX-API-DMAC10.html)
EP (1) EP4203974A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023543131A (cg-RX-API-DMAC10.html)
KR (1) KR20230104119A (cg-RX-API-DMAC10.html)
CN (1) CN116322644A (cg-RX-API-DMAC10.html)
AU (1) AU2021331487A1 (cg-RX-API-DMAC10.html)
CA (1) CA3189915A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023003656A2 (cg-RX-API-DMAC10.html)
CR (1) CR20230135A (cg-RX-API-DMAC10.html)
IL (1) IL300805A (cg-RX-API-DMAC10.html)
JO (1) JOP20230043A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023002418A (cg-RX-API-DMAC10.html)
PE (1) PE20231169A1 (cg-RX-API-DMAC10.html)
WO (1) WO2022047249A1 (cg-RX-API-DMAC10.html)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4877778A (en) * 1987-07-01 1989-10-31 The Children's Medical Center Corporation Method of enhancing lipophile transport using cyclodextrin derivatives
WO2013155485A2 (en) * 2012-04-13 2013-10-17 Alessia Fornoni Method of using cyclodextrin

Also Published As

Publication number Publication date
EP4203974A1 (en) 2023-07-05
CA3189915A1 (en) 2022-03-03
IL300805A (en) 2023-04-01
CN116322644A (zh) 2023-06-23
KR20230104119A (ko) 2023-07-07
MX2023002418A (es) 2023-07-11
EP4203974A4 (en) 2024-08-07
JP2023543131A (ja) 2023-10-13
JOP20230043A1 (ar) 2023-02-27
CR20230135A (es) 2023-07-19
CO2023003656A2 (es) 2023-08-09
AU2021331487A1 (en) 2023-03-16
WO2022047249A1 (en) 2022-03-03
US20240000826A1 (en) 2024-01-04
US20230091966A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
Bawaskar et al. Indian red scorpion envenoming
CL2022002592A1 (es) Uso de agentes para el tratamiento de condiciones respiratorias
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
Kaplan et al. Role of ranolazine in heart failure: From cellular to clinic perspective
CO5590913A2 (es) Terapia de combinacion antivirica
AR114392A1 (es) Tratamiento de pacientes con enfermedad de fabry clásica
WO2014116097A3 (es) Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox
AR073514A1 (es) Metodos de tratamiento de hiperuricemia y estados de enfermedad asociados
Gibbs et al. Disrupted mitochondrial genes and inflammation following stroke
Brannagan III Current issues in peripheral neuropathy
CL2025003377A1 (es) Tratamiento de afecciones inflamatorias que comprende imu-856.
Wallmüller et al. Limited effect of mild therapeutic hypothermia on outcome after prolonged resuscitation
MX2023010918A (es) Metodos y composiciones para el tratamiento de enfermedades oculares.
AR038632A1 (es) Composicion farmaceutica
Rooney et al. Understanding the psychology of the nocebo effect
Cofan et al. Quality of life in renal transplant recipients following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
AR061635A1 (es) Tratamiento de insuficiencia cardiaca cronica leve en pacientes humanos
Sharma et al. Perioperative myocardial infarction
Estabile et al. The inflammatory nitric oxide mechanism and its participation in cardiac tissue injuries
Virgili Fusidic acid/betamethasone valerate/tacrolimus
Ziga-Martínez et al. Catastrophic presentation of venous thromboembolic disease
Audette Acupuncture-Immune Modulation and the Gut-Lung Axis
Yan et al. Electroacupuncture at “Siguan” acupoints alleviates post-stroke depression by inhibiting ER stress-induced apoptosis in the prefrontal cortex
Parkhomenko et al. Improving efficiency of antioxidant and cytoprotective therapy in patients with NSAID-gastropathy and concomitant ischemic heart disease